{
    "id": 18593,
    "cites": 22,
    "cited_by": 4,
    "reference": [
        "Flynn, S. Hollis, A. Palmedo, M. (2009) An economic justification for open access to essential medicine patents in developing countries. J. Law, Medicine, Ethics, 37(2):184-208.",
        "Danzon, P.M., Mulcahy, A. and Towse, A. (2011). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Pharmaceutical Prices in Emerging Markets: Effects of Income, Competition and Procurement.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d NBER Working Paper 17174. Cambridge MA.",
        "Garber, A. and Phelps, C. (1997). Economic foundations of cost-effectives analysis. Journal of Health Economics, 16, 1-31.",
        "Garber, A., Jones, C.I. and Romer, P.M. (2006). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Insurance and Incentives for Medical Innovation.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Forum for Health Economics and Policy: Vol.9: Iss.2 (Biomedical Research and the Economy, Article 4",
        "Jena, A.B.and Philipson, T.J. (2008) Cost Effectiveness Analysis and Innovation. Journal of Health Economics; 27: 1224-1236",
        "Lakdawalla, D. and Sood, N. (2005) Insurance and Innovation in Health Care Markets. September 2005. NBER Working Paper 11602. Cambridge MA",
        "Lakdawalla, D. and Sood, N. (2009). Innovation and the welfare effects of public drug insurance. Journal of Public Economics; 93: 541-8",
        "Malueg, D., and Schwartz, M. (1994). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Parallel imports, demand dispersion, and international price discrimination.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d J Int\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2l Econ 37:167-195.",
        "Danzon, P. (1997). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Price discrimination for pharmaceuticals: welfare effects in the US and EU.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Int\u00c3\u00a2\u00e2\u0082\u00ac\u00e2\u0084\u00a2l J Econ Business 4(3):301-321.",
        "Danzon, P. and Towse, A. (2003). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Differential pricing for pharmaceuticals: reconciling access, R&D and patents.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d Int J Health Care Finance and Econ 3:183-205.",
        "Jack, W. and Lanjouw, J. O. (2005). Financing pharmaceutical innovation: How much should poor countries contribute? The World Bank Economic Review, 19(1), 45-67.",
        "Szymanski, S. and Valletti, T. (2005). Parallel trade, price discrimination, investment and price caps. Economic Policy, 20(44), 705-749.",
        "Ballard, C. L., Shoven J. B. and Whalley, J. 1985 \"General Equilibrium Computations of the Marginal Welfare Costs of Taxes in the United States.\" American Economic Review 75(1): 128-138.",
        "Goldman, D. and Philipson, T.J. 2007. \"Integrated Insurance Design in the Presence of Multiple Medical Technologies,\" American Economic Review 97(2):427-432, May.",
        "Valletti, T. M. and Szymanski, S. (2006). Parallel trade, international exhaustion and intellectual property rights: A welfare analysis. The Journal of Industrial Economics, 54(4), 499526.",
        "Ramsey F (1927). A contribution to the theory of taxation. Economic Journal 37: 47-61",
        "Baumol, W. and Bradford, D. (1970). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Optimal departures from marginal cost pricing.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d AER 60(3):365-283.",
        "Braeutigam, R. (1984). \u00c3\u00a2\u00e2\u0082\u00ac\u00c5\u0093Socially optimal pricing with rivalry and economies of scale.\u00c3\u00a2\u00e2\u0082\u00ac\u00c2\u009d RAND J Econ 15(1):127-134",
        "Barros,P. and Martinez-Giralt, X. (2008). On international cost-sharing of pharmaceutical R&D. Int J Health Care Finance and Econ 8:301-312.",
        "Danzon, P. and Taylor, E. 2010. Drug Pricing and Value in Oncology. The Oncologist. 15(1)24-31.",
        "Office of Fair Trading (2007). The Pharmaceutical Price Regulation Scheme: An OFT market study. OFT. London",
        "Claxton, K., Briggs, A., Buxton, M.J., Culyer, A.J., McCabe, C., Walker, S. and Sculpher M.J. (2008). Value based pricing for NHS drugs: an opportunity not to be missed? BMJ; 336:251-4."
    ]
}